tbuckley/cabot-search huggingface dataset:
THERAPEUTIC IMPORTANCE OF EXTRA-PYRAMIDAL PHENOMENA EVOKED BY A NEW PHENOTHIAZINE
Authors: JOHN DENHAM, DAVID J. E. L. CARRICK
Journal: American Journal of Psychiatry (1960)

The neurological manifestations evoked RP 7843 were observed to be analogous with those of epidemic encephalitis. These extra-pyramidal disturbances are of value because of the associated therapeutic benefit but also for the control of dosage and as prognostic pointers. This sulphamoyl phenothiazine is of extraordinary value in the treatment of all stages of schizophrenia and raises new theoretical considerations.
Association of Fetuin-A With Mitral Annular Calcification and Aortic Stenosis Among Persons With Coronary Heart Disease
Authors: Joachim H. Ix, Glenn M. Chertow, Michael G. Shlipak, Vincent M. Brandenburg, Markus Ketteler, Mary A. Whooley
Journal: Circulation (2007)

Background— Fetuin-A is a multifunctional hepatic secretory protein that inhibits dystrophic vascular and valvular calcification. Lower serum fetuin-A concentrations are associated with valvular calcification in persons with end-stage renal disease. Whether fetuin-A is associated with valvular calcification in other patient populations is unknown. Methods and Results— We evaluated the associations among serum fetuin-A concentrations, mitral annular calcification, and aortic stenosis in 970 ambulatory persons with coronary heart disease and without severe kidney disease. The presence or absence of mitral annular calcification and aortic stenosis was determined by transthoracic echocardiography. The subjects’ mean age was 66 years; 81% were men; 189 (20%) had mitral annular calcification; and 79 (8%) had aortic stenosis. Participants were categorized by tertiles of fetuin-A concentrations. Those within the highest fetuin-A tertile had significantly lower odds of mitral annular calcification compared with the lowest tertile (adjusted odds ratio, 0.47; 95% confidence interval, 0.29 to 0.77; P =0.002); this association was similar regardless of diabetes status ( P for interaction=0.34). In contrast, the association of fetuin-A with aortic stenosis was modified by the presence or absence of diabetes mellitus ( P for interaction=0.03). Among participants without diabetes, the highest fetuin-A tertile had a significantly lower odds of aortic stenosis compared with the lowest tertile (adjusted odds ratio, 0.37; 95% confidence interval, 0.15 to 0.92; P =0.03), whereas among participants with diabetes, no statistically significant association was observed between fetuin-A and aortic stenosis (adjusted odds ratio, 1.49; 95% confidence interval, 0.48 to 4.63; P =0.49). Conclusions— Among persons with coronary heart disease, we observed an inverse association of fetuin-A and mitral annular calcification. An inverse association also was observed between fetuin-A and aortic stenosis among participants without diabetes mellitus. Fetuin-A may represent an important inhibitor of dystrophic calcification in persons with coronary heart disease.
CORRECTION OF PROGNATHISM OF THE LOWER JAW
Authors: Joseph A. Pettit
Journal: JAMA (1933)

<h3>To the Editor:</h3> —Recently my attention was called to a communication by Dr. Robert H. Ivy (The Journal, Dec. 31, 1932) criticizing an article by Pettit and Walrath (The Journal, Dec. 3, 1932). Apparently his perusal of this article was hasty or casual. In the references quoted he proves that this is really a new procedure for the correction of prognathism, and at the same time he shows an unfamiliarity with either his own references or with our article. The operation of Dufourmentel, to which he refers, is entirely different, is a destructive procedure, shortens the total length of the ramus and its appendages, leaves a flail joint structure with a definite disturbance of muscle attachment, and from an anatomic consideration creates the "makings" of the unfortunate open bite. None of these disadvantages exist in the technic which Walrath and I advocate. He refers to my statement that in operations
THE DOUBLE ENVELOPE TECHNIQUE OVERESTIMATES THE CALCULATED AORTIC VALVE AREA IN PATIENTS WITH SEVERE AORTIC STENOSIS USING TRANSESOPHAGEAL ECHOCARDIOGRAPHY
Authors: Elrond Teo, Omar Khalique, Elana Koss, Leo Marcoff, Jack Shanewise, Rebecca Hahn
Journal: Journal of the American College of Cardiology (2013)
Trazodone and Intrahepatic Cholestasis
Authors: KHALID H. SHEIKH
Journal: Annals of Internal Medicine (1983)

Letters and Corrections1 October 1983Trazodone and Intrahepatic CholestasisKHALID H. SHEIKH, M.D., ALAN S. NIES, M.D.KHALID H. SHEIKH, M.D., ALAN S. NIES, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-99-4-572_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: With reference to the recent report by Chu and associates (1), we report another case of liver toxicity attributed to the use of the antidepressant medication, trazodone.A 71-year-old woman was admitted for evaluation of malaise and jaundice. The patient had been started on trazodone, 50 mg/d, 2 weeks before the onset of symptoms. She was otherwise healthy and took no other medications or alcohol. On admission her bilirubin was 12 mg/dL (normal, less than 1 mg/dL); aspartate transaminase, 780 IU/L (normal less than 60 IU/L); and alkaline phosphatase, 1310 IU/L (normal, less than 120 IU/L). Negative...References1. CHUGUNSOLLYSUMMERSALEXANDERMCCHESNEYTANNA ABRBCV Trazodone and liver toxicity. Ann Intern Med. 1983;99:128-9. LinkGoogle Scholar2. ZIMMERMAN H. Drug induced liver disease. Drugs. 1978;16:24-5. CrossrefGoogle Scholar3. BROGDENITELLSPEIGHTAVERY RRTG. Trazodone: a review of its pharmacologic properties and therapeutic use in depression and anxiety. Drugs. 1981;21:401-29. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Colorado Health Sciences Center Denver, CO 80262 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTrazodoneBiotransformation and bioactivation reactions of alicyclic amines in drug moleculesANTIDEPRESSANTSIn Vitro Assessment of Mitochondrial Dysfunction and Cytotoxicity of Nefazodone, Trazodone, and BuspironeAntidepressant-lnduced Liver InjuryTrazodoneMetabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4Antidepressant-induced hepatotoxicityHepatotoxicity after Short-Term Trazodone TherapyCholestatic jaundice associated with the use of metforminTrazodone-Induced Hepatotoxicity: A Case Report With Comments on Drug-Induced HepatotoxicityHEPATOTOXICITY OF ANESTHETICS AND OTHER CENTRAL NERVOUS SYSTEM DRUGSHepatotoxity9 Drug-induced cholestasisTrazodone-induced hepatotoxicity and leukonychiaAntidepressant drugs 1 October 1983Volume 99, Issue 4Page: 572-572KeywordsAlcoholsAminotransferasesBilirubinLiverPhosphatasesToxicity Issue Published: 1 October 1983 PDF downloadLoading ...
An Experimental Study of the Effect of Chronic Atelectasis on Pulmonary and Bronchial Blood Flow
Authors: RICHARD M. PETERS, WILLIAM E. LORING, WILLIAM H. SPRUNT
Journal: Circulation Research (1959)

Four dogs and one patient with uncomplicated atelectasis of an entire lung were studied. Arterial oxygen saturations were nearly normal, indicating diminished flow to the atelectatic lung. Angiography confirmed this finding. Vinyl plastic injections showed no evidence of increased bronchial collateral circulation and pathological examination of the atelectatic lung did not demonstrate any bronchiectasis.
Immune Responses to Hepatitis B Vaccine With and Without the Pre-S2 Antigen in Children With Type 1 Diabetes
Authors: Michele Mancuso, Manuela Caruso-Nicoletti, Sebastiano Bianca, Giuliana Granata, Giovanni Li Volti, Salvatore Li Volti
Journal: Diabetes Care (2001)

This study involved 20 patients (10 males and 10 females) with type 1 diabetes who were seronegative for hepatitis B surface-antigen (HBsAg) and other hepatitis B (HB) viral markers and had no diabetic complications. As patients were recruited over a period of several months, each patient was alternatively assigned to one of two vaccination groups (A or B). There was no significant difference between groups A and B in terms of age, sex, duration of diabetes, and levels of HbA1c. Written informed parental consent was obtained for all patients. Patients in groups A (mean age 12.7 ± 2.6 years, mean duration of diabetes 5.1 ± 2.6 years, mean HbA1c level 8.6 ± 0.7%) received three doses of 10 or 20 μg (the lower dose was given to patients aged <10 years, as recommended by the manufacterer) of a recombinant DNA HB vaccine (Engerix B; Smith-Kline Beecham, Rixensart, Belgium) by intramuscular injections in the left thigh at 0, 1, and 2 months. Patients in group B (mean age 13.8 ± 5.7 years, mean duration …
Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
Authors: Robert J Lederman, Farrell O Mendelsohn, R David Anderson, Jorge F Saucedo, Alan N Tenaglia, James B Hermiller, William B Hillegass, Krishna Rocha-Singh, Thomas E Moon, MJ Whitehouse, Brian H Annex
Journal: The Lancet (2002)
From the public health conference: The population's health must be paramount
Authors: L Beecham
Journal: BMJ (1994)

In his first year as chairman of the Committee for Public Health Medicine and Community Health Dr Stephen Watkins has tried to ensure that the population's health has been at the forefront of the BMA's discussions. Reporting to the annual conference of public health medicine and community health, which he also chaired, on 14 June, Dr Watkins said that the commitment to the health of the population was the link between the two groups at the conference. The service could be delivered only to a community so it was important that units of health service administration were comparable with local communities, hence the fight for coterminosity between health and local authorities. The chairman said that he found it strange that ministers shared the concern at the loss of common boundaries and then signed orders endorsing authorities which were not coterminous. Dr Watkins believed that the alternative bureaucratic method of commissioning care that was envisaged by some people would fail. This entailed setting a few numerical indicators to be achieved. But not everything that was important was measurable. If it was the data did not exist and if they did they were wrong.

The chairman referred to the Tavistock initiative set up as a result of the chief medical officer's visit to the BMA council in May (21 May, p 1322). Dr Kenneth Calman had asked the profession to put forward its own proposals for the future of the NHS and the profession's role. Dr Watkins hoped that the project would be successful because over the past few years each craft committee had made proposals to the government and they had been ignored. The chairman of council, Dr Sandy Macara, agreed that the project was a challenge and he hoped that the profession would respond in an appropriate way. The first …
Skin Immunofluorescence Studies on Lupus Erythematosus and Other Antinuclear-Antibody-Positive Diseases
Authors: JAY GROSSMAN
Journal: Annals of Internal Medicine (1974)

The deposition of gamma globulins and complement at the dermal-epidermal (D-E) junction of normal-appearing skin was found by direct immunofluorescence in 54% of patients with systemic lupus erythematosus and in only one patient with procainamide-induced lupus. No patients with rheumatoid arthritis or other antinuclear-antibody-positive connective tissue diseases showed this deposition. The D-E junction staining was found only in patients with clinically active systemic lupus erythematosus, but it could not be correlated with specific organ system involvement.
Cholesterol Reduction and Life Expectancy
Authors: WILLIAM C. TAYLOR
Journal: Annals of Internal Medicine (1987)

In deciding whether to undertake a dietary program to reduce serum cholesterol levels, a person must consider how much benefit to expect. We developed a model that assumes cholesterol reduction is effective and safe in reducing the risk for death from ischemic heart disease. In the model, we considered asymptomatic adults with total serum cholesterol levels between 180 and 300 mg/dL. We defined risk status on the basis of blood pressure, smoking habit, and high-density-lipoprotein cholesterol level. For persons aged 20 to 60 years who are at low risk, we calculate a gain in life expectancy of 3 days to 3 months from a lifelong program of cholesterol reduction. For persons who are at high risk, the calculated gain ranges from 18 days to 12 months. Knowledge of the magnitude of the calculated benefits in increased life expectancy afforded by cholesterol reduction can assist persons in making decisions about dietary change.
FOCAL KERATOSIS FOLLICULARIS OVERLYING DERMATOFIBROMA
Authors: A. BERNARD ACKERMAN, LEWIS CAPLAND, ARKADI M. RYWLIN
Journal: British Journal of Dermatology (1971)

Journal Article FOCAL KERATOSIS FOLLICULARIS OVERLYING DERMATOFIBROMA Get access A. BERNARD ACKERMAN, A. BERNARD ACKERMAN Department of Dermatology, the University of Miami School of Medicine Miami, Florida, U.S.A Search for other works by this author on: Oxford Academic Google Scholar LEWIS CAPLAND, LEWIS CAPLAND Department of Dermatology, the University of Miami School of Medicine Miami, Florida, U.S.A Search for other works by this author on: Oxford Academic Google Scholar ARKADI M. RYWLIN ARKADI M. RYWLIN Department of Pathology, Mt Sinai Hospital, the University of Miami School of Medicine Miami, Florida, U.S.A Requests for reprints should be addressed to Dr Rywlin, Mt Sinai Hospital, Miami Beach, Florida, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 84, Issue 2, 1 February 1971, Pages 167–168, https://doi.org/10.1111/j.1365-2133.1971.tb06861.x Published: 01 February 1971 Article history Accepted: 28 July 1970 Published: 01 February 1971
Site-directed mutagenesis of class I HLA genes. Role of glycosylation in surface expression and functional recognition.
Authors: J A Barbosa, J Santos-Aguado, S J Mentzer, J L Strominger, S J Burakoff, P A Biro
Journal: The Journal of Experimental Medicine (1987)

We have investigated the role of the carbohydrate moiety on the HLA-B7 molecule in mAb and CTL recognition using oligonucleotide-directed mutagenesis and gene transfer techniques. A conservative substitution of asparagine to glutamine at amino acid 86 in HLA-B7 was created to abolish the unique glycosylation site present on all HLA molecules. A second mutant B7 molecule was made by substituting asparagine-aspartic acid-threonine for the resident lysine-aspartic acid/lysine tripeptide at amino acids 176-178, thus creating an N-linked glycan at amino acid 176, which is additionally present on all known murine H-2 class I antigens. Upon gene transfer into mouse and human cell recipients, the HLA-B7M176+ mutant and normal HLA-B7 expressed identical levels of surface protein. However, the binding of two mAbs (MB40.2 and MB40.3) thought to recognize different epitopes of the HLA-B7 molecule was completely eliminated. In contrast, the HLA-B7M86- mutant displayed no surface expression (mouse L cells) or minimal surface expression (human RD cells or mouse L cells coexpressing human beta 2 microglobulin [beta 2m]) after indirect immunofluorescence (IIF) and flow cytometric analysis with a panel of 12 HLA-B7 mAb reactive with monomorphic and polymorphic determinants. Immunoprecipitation analysis demonstrated that intracellular denatured mutant protein was present. Tunicamycin treatment did not rescue the expression of HLA-B7M86- antigens to the cell surface; while interferon did induce higher levels of surface expression. Tunicamycin treatment also did not allow binding of the mAbs MB40.2 or MB40.3 to HLA-B7M176+ mutant antigens, suggesting that the carbohydrate moiety itself was not directly involved in the recognition or conformation of these mAb epitopes. Further mutation of the B7M86- molecule to create a glycan moiety at amino acid position 176 (B7M86-/176+) did not rescue normal levels of surface expression. Finally, neither mutation was seen to affect recognition by a panel of 12 allospecific CTL clones. The low expression of HLA-B7M86- on the surface of human cell transfectants was sufficient to achieve lysis, albeit at a reduced efficiency, and lysis could be increased by interferon induction of higher levels of expression. Thus, the carbohydrate moiety on HLA antigens plays a minimal or nonexistent role in recognition by available mAb and allospecific CTL clones.
Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus
Authors: P. Joly, C. Richard, D. Gilbert, P. Courville, O. Chosidow, J.C. Roujeau, M. Beylot-Barry, M. D'Incan, Ph. Martel, Ph. Lauret, F. Tron
Journal: Journal of the American Academy of Dermatology (2000)
Epstein‐Barr virus reactivation in a patient treated with anti‐thymocyte globulin for severe aplastic anemia
Authors: Elisabetta Calistri, Mario Tiribelli, Marta Battista, Angela Michelutti, Mario Corbellino, Pierluigi Viale, Renato Fanin, Daniela Damiani
Journal: American Journal of Hematology (2006)

Abstract Epstein‐Barr virus (EBV) infection and reactivation is an increasing complication in immune deficient patients, particularly after allogeneic hematopoietic stem cell transplantation (HSCT). Therapy with anti‐thymocyte globulin (ATG) is associated with higher incidence of EBV‐related disease in HSCT patients, but this risk is not documented in patients receiving ATG for severe aplastic anemia (SAA). We describe the case of a patient who developed an EBV infection, with the clinical features of an infectious mononucleosis, after immune suppression with cyclosporine and two courses of ATG for SAA. Am. J. Hematol. 81:355–357, 2006. © 2006 Wiley‐Liss, Inc.
Diagnosis and management of alcohol use disorders
Authors: Andrew J R Parker, E Jane Marshall, David M Ball
Journal: BMJ (2008)

Alcohol use disorders account for 4% of the global burden of disease and cause 1.8 million deaths (3.2% of total) each year. 1 The overall economic cost to society is huge-around £20bn (€26.7bn;$39bn) each year in the United Kingdom-mostly as a result of lost productivity and alcohol related crime. 2 Healthcare professionals have a vital role to play in implementing secondary prevention, and in identifying those who need specialist treatment.Well validated screening tools have recently become available, and the effectiveness of early brief interventions and more intensive treatments, together with the cost effectiveness of intensive treatments provide a strong impetus for improving the identification and management of disorders of alcohol misuse. 3 MethodsWe used the term "alcohol" to search the online electronic databases of the World Health Organization (WHO), the Cochrane Library, the National Treatment Agency for Substance Misuse, the National Institute for Health and Clinical Excellence (NICE), and the UK Department of Health for suitable evidence based material and policy documents.How are alcohol use disorders defined?Box 1 lists the categories of alcohol use disorders used by WHO and in an important UK review of treatment for alcohol problems. 3The pattern of drinking and the total weekly consumption of alcohol are important determinants of alcohol related harm, so "binge drinkers" are included in the categories of hazardous drinking and harmful drinking. How common are alcohol use disorders?In England, about 38% of men and 16% of women (26% overall) have an alcohol use disorder, and 6% of men and 2% of women have alcohol dependency. 4Given that per capita alcohol consumption in the UK has doubled in the past 40 years, and deaths from liver cirrhosis continue to rise sharply, such disorders may be increasing in the UK.This contrasts with western Europe as a whole, particularly southern Europe, where per capita alcohol consumption and deaths from liver cirrhosis have decreased over the same period. 5How are alcohol use disorders identified and diagnosed?
Scientists Investigate Routing Latent HIV From Its Reservoirs to Achieve a Cure
Authors: M. J. Friedrich
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study
Authors: J Laurin, K D Lindor, J S Crippin, A Gossard, G J Gores, J Ludwig, J Rakela, D B McGill
Journal: Hepatology (1996)

Non-alcohol-induced steatohepatitis (NASH) is characterized by elevated serum aminotransferase activities with hepatic steatosis, inflammation, and occasionally fibrosis that may progress to cirrhosis. No established treatment exists for this potentially serious disorder. Our aim was to conduct a pilot study to evaluate the safety and estimate the efficacy of ursodeoxycholic acid (UDCA) and clofibrate in the treatment of NASH. Forty patients were diagnosed with NASH based on a compatible liver biopsy with other causes of liver disease, including alcohol abuse, excluded by history, serum tests, and use of ultrasound. Twenty-four patients received 13 to 15 mg/kg/d of UDCA for 12 months. Sixteen patients with hypertriglyceridemia were placed on clofibrate, 2 g/day for 12 months. Twenty-five women and 15 men entered the study. Six of 40 patients (15%) withdrew because of side effects. Four additional patients were withdrawn because of noncompliance; one of them later required liver transplantation. In the UDCA group, the decreases in mean serum levels of alkaline phosphatase, alanine transaminase (ALT), and gamma-glutamyl transpeptidase (GGT) as well as histological grade of steatosis were significant. Among the patients treated with clofibrate, no change from baseline was found in mean ALT, aspartate transaminase (AST), GGT, bilirubin, triglycerides, and cholesterol, or in histological grade of steatosis, inflammation, or fibrosis after 12 months of treatment as compared with entry. Alkaline phosphatase activities decreased significantly from baseline. Despite the known lipid-lowering effects of clofibrate, it did not appear to be of clinical benefit in the treatment of NASH in this 1-year pilot study. However, treatment of NASH with UDCA for 12 months resulted in significant improvement in alkaline phosphatase, ALT, GGT, and hepatic steatosis. The possible benefit of UDCA therapy should be further investigated in the context of a randomized, controlled trial.